Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and <i>TP53</i> mutation status
The MCL35 gene expression assay encompasses key risk features and stratified older patients with mantle cell lymphoma (MCL) using routine biopsies. In the SHINE trial, high-risk patients had poor outcomes despite adding ibrutinib to bendamustine-rituximab, highlighting an urgent need for novel strategies in high-risk MCL.
Authors
- David W. Scott (ORCID: https://orcid.org/0000-0002-0435-5947)
- Todd Henninger
- Srimathi S. Srinivasan (ORCID: https://orcid.org/0000-0001-7202-9425)
- Martin H. Dreyling (ORCID: https://orcid.org/0000-0002-0358-5249)
- Ciara L. Freeman (ORCID: https://orcid.org/0000-0002-0662-6480)
- Sanjay Deshpande (ORCID: https://orcid.org/0000-0003-0064-1329)
- Merrill Boyle
- Michael L. Wang (ORCID: https://orcid.org/0000-0001-9748-5486)
- Brendan Paul Hodkinson (ORCID: https://orcid.org/0009-0007-9892-5827)
Institutions
- Johnson & Johnson (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of British Columbia (CA)
- University of South Florida (US)
- Spinal Cord Injury BC (CA)
- LMU Klinikum (DE)
- Moffitt Cancer Center (US)
- Springhouse (US)
- Johnson & Johnson (Israel) (IL)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Blood
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1182/blood.2024026003
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00